170.00 +0.31 (0.18%)
After hours: 5:25PM EDT
|Bid||169.61 x 800|
|Ask||169.68 x 800|
|Day's range||168.68 - 170.02|
|52-week range||166.30 - 210.19|
|Beta (3Y monthly)||0.90|
|PE ratio (TTM)||13.53|
|Earnings date||24 Jul 2019 - 29 Jul 2019|
|Forward dividend & yield||5.80 (3.23%)|
|1y target est||206.10|
Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.
The drug development pipelines of Gilead Sciences, Amgen and Biogen are running thin, and the companies might need to M&A to get going again, according to JPMorgan.
AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.
Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.
Allergan's (AGN) stock declines slightly in pre-market trading despite the company delivering earnings and revenue beat in the first quarter while marginally raising its guidance
Teva Pharmaceutical (TEVA) beats estimates for earnings but misses the same for sales. Blockbuster drug Copaxone sales continue to erode amid generic competition.
Protalix (PLX) is scheduled to release its first quarter 2019 results on May 6 and we expect the company to provide updates on the pipeline.
Allergan's (AGN) key products like Botox are likely to provide top-line support in Q1 as loss of exclusivity of several products hurts sales
Amgen (AMGN) earnings beat estimates in the first quarter while sales come in line with the same. The company raises the lower end of its previously issued sales and earnings guidance for 2019.
The drugmaker managed to keep sales steady as it seeks to protect its turf against biosimilar competitors for two of its key cancer drugs. It’s still waiting for new products to kick in more strongly.
Shares of Amgen Inc. rose more than 1% in the extended session Tuesday after the drug company reported adjusted first-quarter profit and sales above expectations. Amgen said it earned $2 billion, or $3.18 a share, in the quarter, compared with $2.3 billion, or $3.25 a share, in the year-ago period. Adjusted for one-time items, Amgen earned $3.56 a share, compared with $3.47 a share a year ago. Revenue was flat at $5.6 billion. Analysts polled by FactSet had expected adjusted earnings of $3.48 a share on sales of $5.5 billion. Sales of its drug Neulasta fell 12% mostly because of lower net selling price and inventory changes, Amgen said. Enbrel drug sales rose 4%, which the company pinned on "favorable impacts" from changes in accounting sales estimates. Amgen shares ended the regular trading day down 1%.